地舒单抗初始治疗后减量是否与骨转移癌患者后续骨相关事件、颌骨坏死或骨质疏松性骨折相关?一项全国性回顾性比较研究
该研究利用台湾全民健康保险研究数据库,纳入2012至2020年间接受地舒单抗治疗的35,325例骨转移癌患者中的8,690例合格患者,评估减量策略与结局的关联。结果显示,注射间隔延长至90天以内可维持SRE预防效果且ONJ风险低,但超过90天或累积剂量过低与SRE风险升高相关,更低治疗强度与全因死亡率升高相关。
要点
- 与≥11次注射相比,仅3次注射与更高手术治疗的SRE风险相关(cs-aHR 3.20)。
- 最大注射间隔>90天与更高SRE风险相关(cs-aHR 2.50),但ONJ风险更低。
- 所有减量策略中更低治疗强度均与更高的全因死亡率相关。
核心结论
- 将地舒单抗给药间隔延长至最多90天可维持SRE预防效果并与低ONJ风险相关,但间隔超过90天或累积剂量过低与SRE高风险相关。
研究设计与样本
- 全国性回顾性比较研究,使用台湾全民健康保险研究数据库,纳入8,690例乳腺癌、前列腺癌或肺癌伴影像学确认骨转移并起始地舒单抗治疗的患者。
- 所有给药均为标准120mg注射,剂量减少严格反映给药频率降低,评估三种减量策略:累积注射次数、最大注射间隔、>60天治疗间隙频率。
- 主要结局为手术治疗SRE,次要结局包括手术治疗ONJ、骨质疏松性骨折、全因骨折和全因死亡,采用Cox和Fine-Gray模型计算调整后风险比。
主要发现
- 与≥11次注射相比,仅3次注射与更高手术治疗的SRE风险相关(cs-aHR 3.20 [95%CI 1.22-8.37]; p=0.03),ONJ风险更低(cs-aHR 0.21 [95%CI 0.07-0.65]; p<0.001),骨质疏松性骨折无差异。
- 与间隔≤60天相比,最大间隔>90天与更高SRE风险相关(cs-aHR 2.50 [95%CI 1.35-4.66]; p=0.003),ONJ风险更低(cs-aHR 0.54 [95%CI 0.35-0.81]; p=0.002)。
- 与0次间隙相比,≥2次>60天治疗间隙与更低ONJ风险相关(cs-aHR 0.36 [95%CI 0.18-0.73]; p=0.001),与SRE和骨质疏松性骨折无关联。
- 前列腺癌亚组中,所有三种减量策略均与更高SRE风险相关,如仅3次注射cs-aHR 17.42 [95%CI 1.87-162.50]; p<0.001;乳腺癌和肺癌亚组中减量策略与SRE风险无关联。
- 所有减量策略中更低治疗强度均与更高全因死亡率相关。
关键数值与推荐
- 手术治疗SRE操作定义为骨折手术操作同时伴有骨肿瘤切除手术编码,需病理报告确认。
- 骨质疏松性骨折采用严格手术编码排除定义:使用非创伤性骨折编码并排除同时存在的肿瘤切除或创伤性骨折编码。
- 减量策略基于初始4个月强制三剂诱导后第一年内的治疗模式评估。
临床怎么用
- 临床可考虑将地舒单抗给药间隔适度延长至最多90天以降低ONJ风险而不增加SRE风险。
- 应避免注射间隔超过90天或累积剂量过低,尤其在前列腺癌骨转移患者中,以降低SRE风险。
- 减量决策需权衡ONJ风险降低与SRE风险及死亡率升高,目前证据支持在密切监测下谨慎实施适度减量。
局限性
- 回顾性研究设计,患者基线骨骼并发症风险不等,尽管多变量调整仍可能存在残余混杂。
- 排除了非手术治疗骨折,可能低估SRE总体负担。
- 随访时间中位数19个月,长期结局需更长时间随访验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Denosumab is widely used for preventing skeletal-related events (SREs) in patients with bone metastases. As advances in systemic cancer therapies have improved survival, the long-term safety and efficacy of denosumab warrant reevaluation. Balancing efficacy in preventing SREs with the cumulative risks associated with prolonged denosumab therapy, particularly osteonecrosis of the jaw (ONJ), a rebound phenomenon of accelerated bone turnover after abrupt discontinuation, and subsequent fragility fractures, has become increasingly important. QUESTIONS/PURPOSES: (1) Is a lower cumulative number of denosumab doses associated with the risk of surgically treated SREs, ONJ, osteoporotic fractures, or all-cause mortality after dose reduction? (2) Is an extended maximum injection interval associated with the risk of surgically treated SREs, ONJ, osteoporotic fractures, or all-cause mortality after dose reduction? (3) Is a higher frequency of treatment gaps > 60 days associated with the risk of surgically treated SREs, ONJ, osteoporotic fractures, or all-cause mortality after dose reduction? METHODS: This nationwide retrospective comparative study utilized data from Taiwan's National Health Insurance Research Database, a population-level resource accounting for 99.9% of Taiwan's residents. By capturing comprehensive medical claims with continuous patient enrollment, this database functionally eliminates loss to follow-up, enabling the construction of highly reliable longitudinal patient histories to evaluate long-term treatment patterns and clinical outcomes. We identified 35,325 patients with breast, prostate, or lung cancer with radiologically confirmed skeletal metastases who initiated denosumab therapy between January 1, 2012, and December 31, 2020. We excluded 75.4% (26,635) of patients, primarily because they received < 3 initial injections (36%), died within 1 year (10%), had prior use of a bone-targeting agent (9%), or switched to another bone-targeting agent during follow-up (2%). Among the 24.6% (8690) of eligible patients (median [IQR] age 65 years [58 to 74]; 58% [5039] female), breast cancer was the most common diagnosis (41% [3577]), followed by lung (30% [2577]) and prostate cancer (29% [2536]). Given that all administered doses throughout the study were standard 120-mg injections, dose reduction strictly reflected decreased administration frequency. Three dose reduction strategies were evaluated based on treatment patterns within the first year after receiving a mandatory three-dose induction phase in the initial 4 months: (1) cumulative dosage (3, 4 to 7, 8 to 10, or ≥ 11 injections), (2) maximum injection interval (≤ 60 days, 61 to 90 days, > 90 days, or no further treatment), and (3) frequency of gaps > 60 days (0, 1, ≥ 2, or no further treatment). Following the initial 1-year exposure window, patients were tracked up to a maximum of 3 years (median [IQR] time 19 months [10 to 33]) or until the occurrence of a study outcome or death. The primary outcome was surgically treated SREs. We excluded nonoperatively treated fractures because conservative management lacks pathologic confirmation in claims data, which introduces substantial ascertainment bias by confusing true metastatic events with osteoporotic or traumatic fractures using ICD codes alone. Therefore, to ensure diagnostic accuracy, an SRE was operationally defined as a fracture surgical procedure accompanied by a concurrent bone tumor excision surgical code, which under the national health insurance system requires a confirmatory pathologic report for reimbursement. Secondary outcomes included surgically treated ONJ, osteoporotic fractures, all-cause fractures, and all-cause mortality. To explicitly differentiate true osteoporotic fractures from SREs or high-energy trauma, we utilized a strict surgical code-based exclusionary definition: We isolated surgical procedures utilizing nontraumatic fracture codes while explicitly ruling out any concurrent tumor excision codes or traumatic fracture codes. To evaluate these outcomes, we estimated cause-specific HRs using Cox proportional hazards models. Additionally, to account for the competing risk of mortality, we calculated subdistribution HRs using Fine and Gray models. Without randomization, patients in this retrospective cohort inherently had unequal baseline risks of skeletal complications. To isolate the independent effect of the dosing strategy from inherent baseline imbalances, both models utilized multivariable analyses to calculate adjusted HRs (cause-specific adjusted HR [cs-aHR] for the Cox models and adjusted subdistribution HR [aSHR] for the Fine-Gray models), controlling for observable confounders that independently influence bone fragility, specifically age, sex, comorbidities, baseline medications, and prior fracture history. RESULTS: Compared with patients receiving ≥ 11 doses, patients receiving only three doses were associated with a higher risk of surgically treated SREs (cs-aHR 3.20 [95% confidence interval (CI) 1.22 to 8.37]; p = 0.03) and lower risk of surgically treated ONJ (cs-aHR 0.21 [95% CI 0.07 to 0.65]; p < 0.001), with no difference in surgically treated osteoporotic fractures. Compared with patients with intervals of ≤ 60 days, patients extending the maximum injection interval beyond 90 days were associated with a higher proportion of surgically treated SREs (cs-aHR 2.50 [95% CI 1.35 to 4.66]; p = 0.003) and less surgically treated ONJ (cs-aHR 0.54 [95% CI 0.35 to 0.81]; p = 0.002), with surgically treated osteoporotic fractures again being no different. Compared with patients with 0 gaps, patients experiencing ≥ 2 treatment gaps for > 60 days were associated with a lower risk of surgically treated ONJ (cs-aHR 0.36 [95% CI 0.18 to 0.73]; p = 0.001) but showed no association with surgically treated SREs and osteoporotic fractures. Lower treatment intensity across all strategies was associated with higher all-cause mortality. In subgroup analyses stratified by primary cancer site, dose reduction was associated with a higher risk of surgically treated SREs in patients with prostate cancer across all three strategies. Specifically, patients who cumulated only three doses (cs-aHR 17.42 [95% CI 1.87 to 162.50]; p < 0.001), patients extending their maximum injection interval to no further treatment (cs-aHR 11.15 [95% CI 1.58 to 78.90]; p = 0.02), and patients experiencing a frequency of gaps leading to no further treatment (cs-aHR 11.22 [95% CI 1.59 to 79.23]; p = 0.02) were associated with higher risk of surgically treated SREs. Conversely, dose reduction strategies showed no association with the risk of surgically treated SREs in patients in either the breast or lung cancer subgroups. A lower risk of surgically treated ONJ was consistently observed across all types of dose reduction strategies. Finally, the subgroup findings for surgically treated osteoporotic fractures and all-cause mortality mirrored the overall cohort, demonstrating no association with surgically treated osteoporotic fractures and a generally higher risk of mortality associated with lower treatment intensity across cancer types. CONCLUSION: In this nationwide retrospective comparative study, extending the denosumab dosing interval up to 90 days maintained efficacy against SREs and was associated with a low risk of ONJ. However, dosage intervals beyond 90 days or very low cumulative dosing were associated with a high risk of SREs. These findings support the potential feasibility of modest dose reduction in clinical practice, but they highlight the need for larger controlled trials to confirm the efficacy of extending dosing intervals and adjusting cumulative dosage. LEVEL OF EVIDENCE: Level III, therapeutic study.
引用
- Heng XQ, Lin WH, Yeh CC, et al. Is Dose Reduction After Initial Treatment With Denosumab Associated With Subsequent Skeletal-related Events, Osteonecrosis of the Jaw, or Osteoporotic Fractures in Patients With Metastatic Carcinoma? A Nationwide Retrospective Comparative Study. Clin Orthop Relat Res. 2026. PMID: 42417549. doi:10.1097/CORR.0000000000004052
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。